Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "Royal"

289 News Found

Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab
News | January 29, 2024

Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America


ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO
People | January 24, 2024

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom


NovaBay and Sonoma to market Avenova-branded products in EU through Sonoma’s distributor network
Supply Chain | January 16, 2024

NovaBay and Sonoma to market Avenova-branded products in EU through Sonoma’s distributor network

Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products


Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.


Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
News | January 07, 2024

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.


AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
News | January 07, 2024

AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan

The deal includes upfront payments, milestone payments and ongoing royalties


Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
News | January 03, 2024

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes


Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension
Clinical Trials | December 28, 2023

Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension

Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908


Elpiscience and Astellas collaborate for novel bispecific macrophage engager
News | December 28, 2023

Elpiscience and Astellas collaborate for novel bispecific macrophage engager

Elpiscience will receive up to US $37 million, including the upfront payment and license option fees


Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion
News | December 14, 2023

Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion

Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid